Advanced Enzyme Technologies Announces Share Buyback

Maximum Buyback Size: ₹69.7 crore
Profit After Tax (Consolidated, Q1 FY27): ₹38.57 crore

Reader Takeaway: Share buyback to enhance EPS; funded by reserves, not debt.

What just happened

Advanced Enzyme Technologies has approved a share buyback program of up to ₹69.7 crore. The buyback will be executed through the open market on stock exchanges. The maximum buyback price is set at ₹500 per share, and the program is scheduled to run from August 14, 2026, to November 20, 2026.

Why this matters

This buyback is intended to enhance shareholder value by reducing the number of outstanding equity shares. This can lead to an increase in key financial metrics like Earnings Per Share (EPS). The company has confirmed that the buyback will be funded from its existing free reserves, avoiding the use of borrowed funds.

The backstory

For the quarter ended June 30, 2026, Advanced Enzyme Technologies reported a consolidated total income of ₹202.81 crore and a Profit After Tax of ₹38.57 crore. Promoter shareholding currently stands at 43.24% as of August 8, 2026. The company is committed to utilizing at least 75% of the maximum buyback size.

What changes now

The buyback program provides a mechanism for the company to return surplus capital to its shareholders. Existing shareholders may see an increase in their proportional ownership and potentially improved EPS. The reduction in outstanding shares could also positively impact the stock price, depending on market conditions.

Risks to watch

While the buyback is funded by reserves, investors should monitor the execution pace and pricing against the maximum limit. Market conditions and the company's ongoing performance will influence the effectiveness of the buyback. There's also a regulatory requirement to use at least 75% of the maximum buyback size.

Peer comparison

Share buybacks are a common capital allocation strategy among listed companies. Companies often use them to signal confidence in their future prospects and to return value when they believe their stock is undervalued. Other companies in the specialty enzyme sector may also consider similar capital return policies.